# Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

> **NCT04988386** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eidos Therapeutics, a BridgeBio company** · enrollment: 389 (actual)

## Conditions studied

- Amyloid Cardiomyopathy, Transthyretin-Related

## Interventions

- **DRUG:** Acoramidis (AG10)

## Key facts

- **NCT ID:** NCT04988386
- **Lead sponsor:** Eidos Therapeutics, a BridgeBio company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-27
- **Primary completion:** 2028-04-15
- **Final completion:** 2028-05-15
- **Target enrollment:** 389 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04988386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04988386, "Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04988386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*